

The Eurofins Discovery PRODUCTS COMPANY

PathHunter® Growth Hormone Bioassay Kit

Qualified with Human Growth Hormone

93-0756Y3-00023 (2-Plate Kit) 93-0756Y3-00024 (10-Plate Kit)

OUR EXPERTISE IN YOUR HANDS. DISCOVER CONFIDENTLY.


Growth Hormone Bioassay Principle



For treatment of growth hormone deficiency

Molecular Mechanism of Action

Assay Principle



Source: Rosenfeld, R.G., et. al. Trends in Endocrinology & Metabolism Volume 18, ISSUE 4, P134-141, May 01, 2007

PathHunter® Growth Hormone Bioassay Kit



Kit Components

List of Components	93-0756Y3-00023	93-0756Y3-00024	
PathHunter U2OS GHR-JAK1 Bioassay Cells	2 vials	10 vials	
PathHunter Bioassay Detection Kit			
Detection Reagent 1 (mL)	2	10	
Detection Reagent 2 (mL)	8	40	
AssayComplete™ Cell Plating Reagent 4	1 X 100 mL	3 X 100 mL	
Assay Complete Dilution Buffer B5	1 X 100 mL	1 X 100 mL	
Control Agonist (hGH)	1 vial	1 vial	
96-well Clear-Bottom TC Treated, Sterile Plates w/lid	2 plates	10 plates	

^{*}Excess reagent may be left in the bottle, after using the volumes needed to run all the plates




The Eurofins Discovery PRODUCTS COMPANY

Sample data

Growth Hormone Bioassay Qualification

Bioassay Workflow

Simple, Homogenous and Rapid Protocol






Assay Parameters Assessed


- % CV between 8 full plate DRCs
- Plate uniformity: EC₈₀ across entire plate
- Plate-to-Plate variability: 3 plates with full plate DRCs run on 3 days
- Slope consistency
- Accuracy, precision, linearity and parallelism of relative potency assay across range of 50-150% from two operators:
 - Assay developer
 - Assay qualifier




The Eurofins Discovery PRODUCTS COMPANY

Plate to plate variability: 3 plates with full plate DRC - same day (Day 3)







Parameter	R1	R2	R3
S/B	7.9	7.8	7.8
Hill Slope	1.460	1.671	1.304
EC ₅₀ (ng/mL)	36.59	35.81	38.44

Parameter	R1	R2	R3
S/B	7.8	7.1	7.4
Hill Slope	1.093	1.462	1.411
EC ₅₀ (ng/mL)	42.08	36.03	41.90


Parameter	R1	R2	R3	
S/B	6.6	7.6	8.1	
Hill Slope	1.545	1.551	1.310	
EC ₅₀ (ng/mL)	39.32	36.60	38.99	



The Eurofins Discovery PRODUCTS COMPANY

Relative Potency, Linearity, Accuracy and Precision

Expected RP (%)	Experiment #	Analyst #	Measured RP (%)	Average RP (%)	% RSD	% Recovery
	1	1	154.2		5.0	101.2
450	2	1	146.3	454.0		
150	3	1	144.9	151.8	5.2	
	4	2	161.9			
	1	1	126.2		3.2	97.7
405	2	1	122.3	122.1		
125	3	1	116.8			
	4	2	123.1			
	1	1	71.2		4.3	95.1
75	2	1	73.3			
75	3	1	73.6	71.3		
	4	2	67			
	1	1	45.9			05.0
50	2	1	46.9	47.0		
50	3	1	44.8	47.6 7.4		95.2
	4	2	52.7			



Accuracy: 97.3% Precision: 7.4%



The Eurofins Discovery PRODUCTS COMPANY

Assay Robustness

Repeatability and Intermediate Precision (Inter-Plate)

Plate #	Experiment #	R2	S/B	EC ₅₀ (ng/mL)	Mean EC ₅₀ (ng/mL)	SD	%RSD
	R1	0.984	7.9	36.59			
1	R2	0.992	7.8	35.81			
	R3	0.995	7.8	38.44			
	R1	0.989	7.8	42.08			
2	R2	0.998	7.1	36.03	38.42	2.39	6.2
	R3	0.994	7.4	41.90			
	R1	0.9843	6.6	39.32			
3	R2	0.9915	7.6	36.60			
	R3	0.9943	8.1	38.99			

Intermediate Precision (Inter-Day)


Day	EC _{50,} ng/mL	Mean EC _{50,} ng/mL		%RSD, EC ₅₀
1	52.1			
2	51.5	47.33	7.71	16.35
3	38.4			

Intermediate Precision (Inter-Plate): 6.2% Intermediate Precision (Inter-Day): 16.4%



The Eurofins Discovery PRODUCTS COMPANY

Parallelism and Potency Estimation (PLA):



Benefits for "Ready-to-Use" Bioassay Kits



The Eurofins Discovery **PRODUCTS COMPANY**

Functional response based on drug MOA
Verified and Qualified with innovator drug
Simple protocol; Rapid results
Specific and Sensitive assay

Readily Implement with Optimized kit

- Frozen ready-to-assay cells
- Bioassay Detection Reagents
- Cell Plating Reagent
- Dilution Buffer

Highly reproducible

- Control Agonist
- Tissue Culture-Treated Plates

For More Info, Questions or Technical Support





Web:

Cell-Based Bioassays for Biologics

Technical Support

For NA:

DRX_SupportUS@eurofinsUS.com

For Europe, Africa & Middle East:

DRX_SupportEurope@eurofinsUS.com

For Asia-Pacific:

AsiaPacificSupport@eurofins.com